secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2026-05-28T16:41:22+00:00
Accession:  0001140361-26-023093
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bepirovirsen Phase 3 achieves 19% functional cure rate in chronic hepatitis B; Q3 2026 FDA decision expected
--------------------------------------------------------------------------------

- 19% functional cure rate (233/1,220) vs 0% placebo (p<0.001) in overall population (HBsAg ≤3000 IU/mL).
- 26% functional cure rate in patients with ≤1000 IU/mL HBsAg, representing ~45% of diagnosed CHB cases globally.
- 49% of bepirovirsen recipients achieved qHBsAg ≤100 IU/mL one year post-treatment in exploratory analysis.
- Bepirovirsen under priority FDA review (Breakthrough/Fast Track); first regulatory decisions anticipated in Q3 2026.
- Ionis eligible for tiered royalties of 10-12% on net sales plus milestones under 2019 GSK license.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036126023093/0001140361-26-023093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036126023093/ef20075060_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-023093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer